复星医药：关于控股子公司药品获临床试验批准的公告

证券日报09-08 21:01

9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。（文章来源：证券日报）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2665937379?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665937379","market":"us","top_or_hot":-1,"title":"复星医药：关于控股子公司药品获临床试验批准的公告","media":"证券日报","content":"<div>\n<p>9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。（文章来源：证券日报）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609083868301376.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药：关于控股子公司药品获临床试验批准的公告</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药：关于控股子公司药品获临床试验批准的公告\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-08 21:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609083868301376.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。（文章来源：证券日报）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609083868301376.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609083868301376.html","article_id":"2665937379","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868301376.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2665937379","pubTimestamp":1788872460,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0196":"行业龙头","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0239":"医药制造","BK0096":"民营医院","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","02196":"复星医药","BMED":"iShares Health Innovation Active ETF","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1191":"制药","PSYK":"PSYK ETF","BK1593":"医美概念股","BK0175":"白马股","BK0060":"抗癌","BK1515":"抗疫概念"},"translate_title":"Fosun Pharma: Announcement Regarding the Approval of Clinical Trials for its Holding Subsidiary's Drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"IBBJ":1.5,"MDTX":1.5,"PSYK":1.5,"IBBQ":1.5,"BMED":1.5,"02196":1.5},"content_text":"9月8日，复星医药发布公告称，公司控股子公司上海复星医药产业发展有限公司近日收到国家药品监督管理局关于同意FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。（文章来源：证券日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665937379","isCrawlerRequest":true}